This effect on treatment response was observed for fluoropyrimidine regimens, platinum-based regimens, and, interestingly, in response to trastuzumab for HER2-positive GC: in a cohort of patients with gastric cancer with HER2 expression, patients whose tumors presented FGFR2 overexpression had worse response to trastuzumab compared to the FGFR2-negative group [32,60,61,62,63]. This evidence concerns the gene ERBB2 and gastric cancer.